Genetic Technology Alert. Innovative Cell-Free DNA Blood Test to Detect Down Syndrome; Novel Experimental Vaccine for Ebola; Novel Antibody Therapy to Reduce HIV Loads

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles an innovative cell-free DNA blood test to detect Down syndrome, a novel experimental vaccine for Ebola, and a novel antibody therapy to reduce HIV loads.

Table of Contents

Genetic Technology Alert. Innovative Cell-Free DNA Blood Test to Detect Down Syndrome; Novel Experimental Vaccine for Ebola; Novel Antibody Therapy to Reduce HIV LoadsIn This Issue1. INNOVATIVE CELL-FREE DNA BLOOD TEST TO DETECT DOWN SYNDROME2. NOVEL EXPERIMENTAL VACCINE FOR EBOLA3. NOVEL ANTIBODY THERAPY TO REDUCE HIV LOADS4. PATENT ANALYSIS OF GENETIC TESTS AND GENOMIC BIOMARKERS




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 31-Oct-17

Region : Global

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.